Penserra Capital Management LLC Grows Stock Position in Ginkgo Bioworks Holdings, Inc. $DNA

Penserra Capital Management LLC grew its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 263.8% during the second quarter, Holdings Channel reports. The institutional investor owned 12,786 shares of the company’s stock after purchasing an additional 9,271 shares during the quarter. Penserra Capital Management LLC’s holdings in Ginkgo Bioworks were worth $143,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in DNA. Bank of New York Mellon Corp increased its holdings in Ginkgo Bioworks by 14.4% in the 1st quarter. Bank of New York Mellon Corp now owns 26,392 shares of the company’s stock worth $150,000 after acquiring an additional 3,331 shares during the last quarter. CWM LLC raised its position in shares of Ginkgo Bioworks by 667.6% in the first quarter. CWM LLC now owns 12,274 shares of the company’s stock valued at $70,000 after purchasing an additional 10,675 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Ginkgo Bioworks in the first quarter valued at approximately $587,000. Forbes J M & Co. LLP boosted its holdings in Ginkgo Bioworks by 56.0% in the 1st quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company’s stock worth $6,239,000 after buying an additional 392,832 shares during the period. Finally, Prescott Group Capital Management L.L.C. raised its stake in shares of Ginkgo Bioworks by 1.1% during the 1st quarter. Prescott Group Capital Management L.L.C. now owns 365,717 shares of the company’s stock valued at $2,085,000 after purchasing an additional 3,967 shares during the period. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Trading Down 4.1%

Shares of NYSE DNA opened at $8.02 on Friday. The firm has a fifty day simple moving average of $12.34 and a two-hundred day simple moving average of $10.91. The firm has a market capitalization of $474.49 million, a PE ratio of -1.29 and a beta of 1.53. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.00 and a 12 month high of $17.58.

Ginkgo Bioworks (NYSE:DNA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.21). Ginkgo Bioworks had a negative return on equity of 51.15% and a negative net margin of 188.00%.The company had revenue of $38.84 million during the quarter, compared to the consensus estimate of $38.95 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Wall Street Analyst Weigh In

DNA has been the subject of a number of recent analyst reports. BTIG Research lifted their target price on Ginkgo Bioworks from $6.00 to $9.00 and gave the company a “sell” rating in a report on Monday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Cowen reissued a “buy” rating on shares of Ginkgo Bioworks in a report on Friday, August 8th. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, Ginkgo Bioworks presently has a consensus rating of “Reduce” and a consensus target price of $9.00.

Insider Activity at Ginkgo Bioworks

In related news, insider Steven P. Coen sold 5,609 shares of Ginkgo Bioworks stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $15.00, for a total transaction of $84,135.00. Following the sale, the insider directly owned 5,503 shares in the company, valued at $82,545. The trade was a 50.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.72% of the stock is currently owned by insiders.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.